BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

723 related articles for article (PubMed ID: 34244052)

  • 61. Impact of GATA-3 and FOXA1 expression in patients with hormone receptor-positive/HER2-negative breast cancer.
    Hisamatsu Y; Tokunaga E; Yamashita N; Akiyoshi S; Okada S; Nakashima Y; Taketani K; Aishima S; Oda Y; Morita M; Maehara Y
    Breast Cancer; 2015 Sep; 22(5):520-8. PubMed ID: 24415069
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival.
    Onitilo AA; Engel JM; Greenlee RT; Mukesh BN
    Clin Med Res; 2009 Jun; 7(1-2):4-13. PubMed ID: 19574486
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].
    Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH
    Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):520-5. PubMed ID: 21029696
    [TBL] [Abstract][Full Text] [Related]  

  • 64. ETS transcription factor ESE-1/Elf3 is an independent prognostic factor of survival in HR
    Kar A; Koto K; Walker D; Trudeau T; Edgerton S; Thor A; Gutierrez-Hartmann A
    Breast Cancer Res Treat; 2020 Aug; 182(3):601-612. PubMed ID: 32562116
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Prognostic and Predictive Impact of Beta-2 Adrenergic Receptor Expression in HER2-Positive Breast Cancer.
    Caparica R; Richard F; Brandão M; Awada A; Sotiriou C; de Azambuja E
    Clin Breast Cancer; 2020 Jun; 20(3):262-273.e7. PubMed ID: 32229175
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Estrogen receptor, Progesterone receptor, HER2 status and Ki67 index and responsiveness to adjuvant tamoxifen in postmenopausal high-risk breast cancer patients enrolled in the DBCG 77C trial.
    Knoop AS; Lænkholm AV; Jensen MB; Nielsen KV; Andersen J; Nielsen D; Ejlertsen B;
    Eur J Cancer; 2014 May; 50(8):1412-21. PubMed ID: 24675287
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network.
    Lin NU; Vanderplas A; Hughes ME; Theriault RL; Edge SB; Wong YN; Blayney DW; Niland JC; Winer EP; Weeks JC
    Cancer; 2012 Nov; 118(22):5463-72. PubMed ID: 22544643
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Clinical Features and Prognosis Analysis of Hormone Receptor-Positive, HER2-Negative Breast Cancer with Differential Expression Levels of Estrogen and Progesterone Receptors: A 10-Year Retrospective Study.
    Liu J; Gan M; Lin Z; Deng Q; Deng J; Zeng B; Shi Y; Ming J
    Breast J; 2022; 2022():5469163. PubMed ID: 36531979
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Age related influence of triple receptor status on metastatic breast cancer post relapse survival.
    Todorovic-Rakovic N; Neskovic-Konstantinovic Z
    J BUON; 2013; 18(4):851-8. PubMed ID: 24344008
    [TBL] [Abstract][Full Text] [Related]  

  • 70.
    Groheux D; Martineau A; Teixeira L; Espié M; de Cremoux P; Bertheau P; Merlet P; Lemarignier C
    Breast Cancer Res; 2017 Jan; 19(1):3. PubMed ID: 28057031
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Real-World Data on Pathological Response and Survival Outcomes After Neoadjuvant Chemotherapy in HER2-Low Breast Cancer Patients.
    Guan D; Shi Q; Zheng Y; Zheng C; Meng X
    Clin Breast Cancer; 2024 Jul; 24(5):463-472.e2. PubMed ID: 38744585
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Androgen receptor expression in a Sri Lankan patient cohort with early breast carcinoma.
    Wijesinghe HD; Wijesinghe GK; Mansoor Z; Vigneshwara S; Fernando J; Gunasekera D; Lokuhetty MDS
    BMC Womens Health; 2020 Sep; 20(1):206. PubMed ID: 32928183
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression.
    Lindström LS; Karlsson E; Wilking UM; Johansson U; Hartman J; Lidbrink EK; Hatschek T; Skoog L; Bergh J
    J Clin Oncol; 2012 Jul; 30(21):2601-8. PubMed ID: 22711854
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Profile and outcome of receptor conversion in breast cancer metastases: a nation-wide multicenter epidemiological study.
    Yi ZB; Yu P; Zhang S; Wang WN; Han YQ; Ouyang QC; Yan M; Wang XJ; Hu XC; Jiang ZF; Huang T; Tong ZS; Wang SS; Yin YM; Li H; Yang RX; Yang HW; Teng YE; Sun T; Cai L; Li HY; Chen X; He JJ; Liu XL; Yang SE; Wang JY; Fan JH; Qiao YL; Xu BH
    Int J Cancer; 2021 Feb; 148(3):692-701. PubMed ID: 32700765
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Adding hormonal therapy to chemotherapy and trastuzumab improves prognosis in patients with hormone receptor-positive and human epidermal growth factor receptor 2-positive primary breast cancer.
    Hayashi N; Niikura N; Yamauchi H; Nakamura S; Ueno NT
    Breast Cancer Res Treat; 2013 Jan; 137(2):523-31. PubMed ID: 23184079
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Metastatic breast carcinoma in pleural fluid: Correlation of receptor and HER2 status with the primary carcinoma-a pilot study.
    Francis IM; Alath P; George SS; Jaragh M; Al Jassar A; Kapila K
    Diagn Cytopathol; 2016 Dec; 44(12):980-986. PubMed ID: 27666130
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Hormonal Receptor, Human Epidermal Growth Factor and Its Association with Breast Cancer Tumor Characteristics in Albania.
    Pajenga E; Rexha T; Çeliku S; Ugrinska A; Bejtja G
    Cent Eur J Public Health; 2016 Sep; 24(3):171-175. PubMed ID: 27760283
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Relationship between body mass index and the expression of hormone receptors or human epidermal growth factor receptor 2 with respect to breast cancer survival.
    Jeon YW; Kang SH; Park MH; Lim W; Cho SH; Suh YJ
    BMC Cancer; 2015 Nov; 15():865. PubMed ID: 26546331
    [TBL] [Abstract][Full Text] [Related]  

  • 79. ER
    Arciero CA; Guo Y; Jiang R; Behera M; O'Regan R; Peng L; Li X
    Clin Breast Cancer; 2019 Aug; 19(4):236-245. PubMed ID: 30846407
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Breast cancer during follow-up and progression - A population based cohort on new cancers and changed biology.
    Karlsson E; Appelgren J; Solterbeck A; Bergenheim M; Alvariza V; Bergh J
    Eur J Cancer; 2014 Nov; 50(17):2916-24. PubMed ID: 25241230
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.